Evidence for functional endothelin-converting enzyme activity in isolated rat basilar artery: Effect of inhibitors

Journal of Cardiovascular Pharmacology

Volumn 31, Issue SUPPL. 1, 1998, Pages

  Vatter, H ^a   Schilling, L ^a   Schmiedek, P ^a   Ehrenreich, H ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Big endothelin 1; ECE inhibitors; Phosphoramidon; Rat basilar artery; Thiorphan; 22Phe big Et 1 19 37

Indexed keywords

ASPARTIC PROTEINASE; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN-CONVERTING ENZYME 1; GLYCOPEPTIDE; METALLOPROTEINASE; PHOSPHORAMIDON; PROTEINASE INHIBITOR; THIORPHAN;

ANIMAL; ARTICLE; BASILAR ARTERY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; IN VITRO STUDY; MALE; METABOLISM; MUSCLE CONTRACTION; RAT; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; ASPARTIC ENDOPEPTIDASES; BASILAR ARTERY; GLYCOPEPTIDES; MALE; METALLOENDOPEPTIDASES; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; THIORPHAN;

EID: 0031639676     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199800001-00021     Document Type: Article

References (24)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
2. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46:325-415.
3. Feger GI, Schilling L, Ehrenreich H, Wahl M. Endothelin induced contraction and relaxation of rat isolated basilar artery: effect of BQ-123. J Cerebr Blood Flow Metab 1994;14:845-52.
4. B-type endothelin receptor. J Cerebr Blood Flow Metab 1995;15:699-705.
5. Schilling L, Feger GI, Ehrenreich H, Wahl M. Cerebrovascular effects of endothelin-3: modulation of contraction by nitric oxide is independent of endothelin B receptor activation. Neurol Res 1996; 18:281-5.
6. B receptor activation. Res Exp Med 1997;196:327-37.
7. Hirose H, Ide K, Sasaki T, et al. The role of endothelin and nitric oxide in modulation of normal and spastic cerebral vascular tone in the dog. Eur J Pharmacol 1995;277:77-87.
8. Cardell LO, Uddman R, Edvinsson L. Endothelins: a role in cerebrovascular disease? Cephalalgia 1994;14:259-65.
9. Ferro JF, Webb DJ. The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Drugs 1996;51:12-27.
10. Ehrenreich H, Schilling L. New developments in understanding cerebral vasoregulation and vasospasm. The endothelin-nitric oxide network. Cleveland Clin J Med 1995;62:105-16.
11. Salom JB, Torregrosa G, Alborch E. Endothelins and the cerebral circulation. Cerebrovasc Brain Metab Rev 1995;7:131-52.
12. Clozel M, Breu V, Burri K, et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993;365:759-61.
13. Foley PL, Caner HH, Kassell NF, Lee KS. Reversal of subarachnoid hemorrhage-induced vasoconstriction with an endothelin receptor antagonist. Neurosurgery 1994;34:108-13.
14. Shigeno T, Clozel M, Sakai S, Saito A, Goto K. The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Neurosurgery 1995;37:87-91.
15. Roux S, Löffler B-M, Gray GA, Sprecher U, Clozel M, Clozel J-P. The role of endothelin in experimental cerebral vasospasm. Neurosurgery 1995;37:78-86.
16. Zuccarello M, Soattin GB, Lewis AI, Breu V, Hallak H, Rapoport RM. Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists. J Neurosurg 1996;84:503-7.
17. Turner AJ, Murphy LJ. Molecular pharmacology of endothelin converting enzymes. Biochem Pharmacol 1996;51:91-102.
18. 22]-big endothelin-1[19-37]: a new and potent inhibitor of the endothelin-converting enzyme. J Cardiovasc Pharmacol 1995;26 (suppl 3):S72-4.
19. Poulat P, De Champlain J, D'Orleans-Juste P, Couture R. Receptor and mechanism that mediate endothelin- and big endothelin-1-induced phosphoinositide hydrolysis in the rat spinal cord. Eur J Pharmacol 1996;315:327-34.
20. McMahon EG, Palomo MA, Moore WM, McDonald JF, Stern MK. Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro. Proc Natl Acad Sci USA 1991;88:703-7.
21. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidone-sensitive metalloprotease with acidic pH optimum. J Biol Chem 1995;270:15262-8.
22. Chen L, McNeill R, Wilson TW, Gopalakrishnan V. Differential effects of phosphoramidon on contractile responses to angiotensin II in rat blood vessels. Br J Pharmacol 1995;114:1599-604.
23. Gardiner SM, Compton AM, Kemp PA, Bennett T. The effects of phosphoramidon on the regional haemodynamic responses to human proendothelin [1-38] in conscious rats. Br J Pharmacol 1991; 103:2009-15.
24. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344:852-4.